WO2013100876A1 - Risperidone formulations - Google Patents

Risperidone formulations Download PDF

Info

Publication number
WO2013100876A1
WO2013100876A1 PCT/TR2012/000231 TR2012000231W WO2013100876A1 WO 2013100876 A1 WO2013100876 A1 WO 2013100876A1 TR 2012000231 W TR2012000231 W TR 2012000231W WO 2013100876 A1 WO2013100876 A1 WO 2013100876A1
Authority
WO
WIPO (PCT)
Prior art keywords
risperidone
range
formulation
weight
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2012/000231
Other languages
French (fr)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013100876A1 publication Critical patent/WO2013100876A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to pharmaceutical formulations comprising risperidone that shall be used in the treatment of schizophrenia, affective symptoms related to schizophrenia, manic episodes of bipolar disorder and restlessness related to autistic disorder.
  • Risperidone was first disclosed in the application numbered EP 196132. In said document, it has been disclosed that risperidone is effective when used in the treatment of psychotic disorders.
  • Risperidone is available in the forms of 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg effervescent tablet, film coated tablet, orodispersible tablet, 1 mg/ml oral solution and 25 mg, 37.5 mg, 50 mg vials for injection on the market.
  • the formulations comprising risperidone are formulated in solid oral dosage forms such as tablet, some problems are encountered regarding dissolution in the body, disintegration rate and homogeneity of the tablets obtained.
  • the formulations comprising risperidone are prepared in film coated tablet form, it is seen that the tablets obtained do not dissolve effectively in gastrointestinal liquid and dispersion of the tablets in the liquid is slow after they are taken into the body. This leads to reduction in absorption of the active agent risperidone comprised in the drug into the blood circulation. Said reduction in absorption of the drug brings with the problems such as decrease in bioavailability of the drug and difficulty in utilizing the drug treatment effectively for the patient.
  • risperidone formulations formulated in film tablet form dissolve rapidly and homogenously in body and therefore an efficient treatment is provided since absorption and bioavailability of the drug are high in the case that they comprise a composition which is composed of at least two different diluting agents as the diluent and in the case that the first diluting agent composing this composition is selected from cellulose based excipients and the second diluting agent is selected from monosaccharides or disaccharides.
  • the present invention relates to the pharmaceutical formulations comprising risperidone.
  • risperidone formulations which are formulated in film tablet form dissolve rapidly and homogenously in body and therefore an efficient treatment is provided since absorption and bioavailability of the drug are high in the case that they comprise a composition composed of at least two different diluting agents as the diluent and in the case that the first diluting agent composing this composition is selected from cellulose based excipients and the second diluting agent is selected from monosaccharides or disaccharides.
  • the first aspect of the present invention is risperidone formulations formulated in film tablet form comprising a composition composed of at least two different diluting agents as the diluent wherein the first diluting agent composing this composition is selected from cellulose based excipients and the second diluting agent is selected from monosaccharides or disaccharides.
  • film tablet formulations comprising risperidone and a diluent composition wherein the ratio of the first diluting agen the second diluting agent is in the range of 1 : 1 to 1 : 10 by weight, preferably in the range of 1 :2 to 1 :8 by weight.
  • another aspect of the present invention is film tablet formulations comprising risperidone wherein the ratio of the first diluting agen the second diluting agent is in the range of 1 : 1 to 1 : 10 by weight, preferably in the range of 1 :2 to 1 :8 by weight.
  • the first diluting agent can be selected from a group comprising microcrystalline cellulose, silicated microcrystalline, cellulose acetate, modified cellulose and/or a combination thereof in the formulations of the present invention.
  • microcrystalline cellulose is preferably used as the first diluting agent.
  • the second diluting agent can be selected from a group comprising glucose, fructose, galactose, lactose, maltose, sucrose and a combination thereof in the formulations of the present invention.
  • lactose can be used as the second diluting agent in the present invention.
  • lactose in hydrate form preferably lactose monohydrate can be used as the second diluent.
  • the formulation comprising risperidone, characterized in that the ratio of microcrystalline cellulose:lactose monohydrate is in the range of 1 : 1 to 1 : 10 by weight, preferably in the range of 1 :2 to 1 :8 by weight.
  • the active agent risperidone is used in the range of 0.05-10%, preferably in the range of 0.1-8%, more preferably in the range of 0.5-5% in proportion to total weight of the unit dose amount.
  • Risperidone comprised in the pharmaceutical formulations of the present invention can be in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination thereof in terms of chemical structure.
  • the diluent composition which is used as the diluent is used in the range of 30-99%, preferably in the range of 40-95%, more preferably in the range of 50-90% in proportion to total weight of the unit dose amount.
  • the excipients in the formulation and amount of use of these excipients in proportion to the active agent affect compressibility, solubility, therefore absorption and bioavailability of the tablets obtained in the tablet formulations comprising risperidone significantly.
  • the ratio of risperidone:diluent composition is in the range of 1 : 10 to 1 :80 by weight, preferably in the range of 1 : 15 to 1 :70 by weight, more preferably in the range of 1 :20 to 1 :65 by weight.
  • film tablet formulations comprising risperidone wherein the ratio of risperidone:diluent composition is in the range of 1 :10 to 1 :80 by weight, preferably in the range of 1 :15 to 1 :70 by weight, more preferably in the range of 1 :20 to 1 :65 by weight.
  • the pharmaceutical formulations of the present invention can comprise at least one pharmaceutically acceptable excipient along with risperidone and diluent composition.
  • the pharmaceutically acceptable excipients that can be used in the formulations of the present invention can be selected from a group comprising lubricant, binder and disintegrant.
  • the disintegrant used in the formulations of the present invention can be selected from a group comprising carboxymethyl cellulose calcium, sodium starch glycolate, carboxymethyl cellulose sodium, microcrystalline cellulose, silicone dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminium silicate, starch or combinations thereof.
  • the binder used in the formulations of the present invention can be selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, starch, hypromellose, magnesium aluminium silicate, methylcellulose, povidone.
  • the lubricant used in the formulations of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
  • a substance from the group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin or a combination thereof, for instance the substance sold on the market under the trademark Opadry Yellow can be used as the film coating agent in the formulations of the present invention.
  • the formulations prepared according to the present invention can comprise disintegrant in the range of 1-50 %, binder in the range of 1-20%, lubricant in the range of 0.1-5%, the coating agent in the range of 0.5 -5% in proportion to total weight of the unit dose amount.
  • the pharmaceutical formulation of the present invention can be obtained by a method comprising the steps of;
  • the pharmaceutical formulation of the present invention can be used in the treatment of schizophrenia, affective symptoms related to schizophrenia, manic episodes of bipolar disorder and restlessness related to autistic disorder.
  • the granulation solution is prepared by mixing one part of the binder with the solvent in obtaining the formulation that shall be used in the present invention. Risperidone, the other part of the binder and one part of the first diluting agent are mixed and sieved. The rest of the first diluting agent, the second diluting agent and powders comprising the disintegrant are stirred in a mixer. The powder mixture obtained is granulated with the granulation solution. The lubricant is added into this mixture and stirred again. The powder mixture obtained is compressed in tablet form and the tablets are coated with the solution comprising the tablet coating agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

RISPERIDONE FORMULATIONS
The present invention relates to pharmaceutical formulations comprising risperidone that shall be used in the treatment of schizophrenia, affective symptoms related to schizophrenia, manic episodes of bipolar disorder and restlessness related to autistic disorder.
Risperidone was first disclosed in the application numbered EP 196132. In said document, it has been disclosed that risperidone is effective when used in the treatment of psychotic disorders.
Figure imgf000002_0001
Risperidone is available in the forms of 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg effervescent tablet, film coated tablet, orodispersible tablet, 1 mg/ml oral solution and 25 mg, 37.5 mg, 50 mg vials for injection on the market.
In the case that the formulations comprising risperidone are formulated in solid oral dosage forms such as tablet, some problems are encountered regarding dissolution in the body, disintegration rate and homogeneity of the tablets obtained. In the case that the formulations comprising risperidone are prepared in film coated tablet form, it is seen that the tablets obtained do not dissolve effectively in gastrointestinal liquid and dispersion of the tablets in the liquid is slow after they are taken into the body. This leads to reduction in absorption of the active agent risperidone comprised in the drug into the blood circulation. Said reduction in absorption of the drug brings with the problems such as decrease in bioavailability of the drug and difficulty in utilizing the drug treatment effectively for the patient.
According to this, there is need for new approaches in order to develop risperidone formulations formulated in film tablet form which can disperse rapidly and homogeneously in body and wherein high absorption and therefore high bioavailability of the active agent risperidone comprised in the formulations are observed during use and which can provide an efficient treatment. The inventors have surprisingly seen that risperidone formulations formulated in film tablet form dissolve rapidly and homogenously in body and therefore an efficient treatment is provided since absorption and bioavailability of the drug are high in the case that they comprise a composition which is composed of at least two different diluting agents as the diluent and in the case that the first diluting agent composing this composition is selected from cellulose based excipients and the second diluting agent is selected from monosaccharides or disaccharides.
Description of the Invention
The present invention relates to the pharmaceutical formulations comprising risperidone. As a result of the studies they conducted in line with this requirement, the inventors have surprisingly seen that risperidone formulations which are formulated in film tablet form dissolve rapidly and homogenously in body and therefore an efficient treatment is provided since absorption and bioavailability of the drug are high in the case that they comprise a composition composed of at least two different diluting agents as the diluent and in the case that the first diluting agent composing this composition is selected from cellulose based excipients and the second diluting agent is selected from monosaccharides or disaccharides.
According to this, the first aspect of the present invention is risperidone formulations formulated in film tablet form comprising a composition composed of at least two different diluting agents as the diluent wherein the first diluting agent composing this composition is selected from cellulose based excipients and the second diluting agent is selected from monosaccharides or disaccharides.
When the prior art is taken into consideration, since problems arise during preparation of film tablets comprising risperidone such as failure to provide proper flow rate and failure to obtain required tablet weights and sizes, there is need for new approaches in order to develop film tablet formulations comprising risperidone.
As a result of the studies they conducted in line with this requirement, the inventors have seen that these problems are eliminated in film tablet formulations comprising risperidone and a diluent composition wherein the ratio of the first diluting agen the second diluting agent is in the range of 1 : 1 to 1 : 10 by weight, preferably in the range of 1 :2 to 1 :8 by weight. According to this, another aspect of the present invention is film tablet formulations comprising risperidone wherein the ratio of the first diluting agen the second diluting agent is in the range of 1 : 1 to 1 : 10 by weight, preferably in the range of 1 :2 to 1 :8 by weight.
The first diluting agent can be selected from a group comprising microcrystalline cellulose, silicated microcrystalline, cellulose acetate, modified cellulose and/or a combination thereof in the formulations of the present invention.
In a preferred embodiment of the present invention, microcrystalline cellulose is preferably used as the first diluting agent.
The second diluting agent can be selected from a group comprising glucose, fructose, galactose, lactose, maltose, sucrose and a combination thereof in the formulations of the present invention.
According to this, lactose can be used as the second diluting agent in the present invention.
In a preferred embodiment of the present invention, preferably lactose in hydrate form, more preferably lactose monohydrate can be used as the second diluent.
According to a preferred embodiment of the present invention, the formulation comprising risperidone, characterized in that the ratio of microcrystalline cellulose:lactose monohydrate is in the range of 1 : 1 to 1 : 10 by weight, preferably in the range of 1 :2 to 1 :8 by weight.
Another characteristic feature of the formulation of the present invention is that the active agent risperidone is used in the range of 0.05-10%, preferably in the range of 0.1-8%, more preferably in the range of 0.5-5% in proportion to total weight of the unit dose amount.
Risperidone comprised in the pharmaceutical formulations of the present invention can be in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination thereof in terms of chemical structure.
Another characteristic feature of the formulation of the present invention is that the diluent composition which is used as the diluent is used in the range of 30-99%, preferably in the range of 40-95%, more preferably in the range of 50-90% in proportion to total weight of the unit dose amount. In the prior art, it is known that the excipients in the formulation and amount of use of these excipients in proportion to the active agent affect compressibility, solubility, therefore absorption and bioavailability of the tablets obtained in the tablet formulations comprising risperidone significantly.
As a result of the studies they conducted in line with this requirement, the inventors have seen that these problems have been overcome in the formulations developed in the manner that the ratio of risperidone:diluent composition is in the range of 1 : 10 to 1 :80 by weight, preferably in the range of 1 : 15 to 1 :70 by weight, more preferably in the range of 1 :20 to 1 :65 by weight.
According to this, another aspect of the present invention is film tablet formulations comprising risperidone wherein the ratio of risperidone:diluent composition is in the range of 1 :10 to 1 :80 by weight, preferably in the range of 1 :15 to 1 :70 by weight, more preferably in the range of 1 :20 to 1 :65 by weight.
The pharmaceutical formulations of the present invention can comprise at least one pharmaceutically acceptable excipient along with risperidone and diluent composition.
The pharmaceutically acceptable excipients that can be used in the formulations of the present invention can be selected from a group comprising lubricant, binder and disintegrant.
The disintegrant used in the formulations of the present invention can be selected from a group comprising carboxymethyl cellulose calcium, sodium starch glycolate, carboxymethyl cellulose sodium, microcrystalline cellulose, silicone dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminium silicate, starch or combinations thereof.
The binder used in the formulations of the present invention can be selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, starch, hypromellose, magnesium aluminium silicate, methylcellulose, povidone.
The lubricant used in the formulations of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
A substance from the group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin or a combination thereof, for instance the substance sold on the market under the trademark Opadry Yellow can be used as the film coating agent in the formulations of the present invention.
The formulations prepared according to the present invention can comprise disintegrant in the range of 1-50 %, binder in the range of 1-20%, lubricant in the range of 0.1-5%, the coating agent in the range of 0.5 -5% in proportion to total weight of the unit dose amount.
The pharmaceutical formulation of the present invention can be obtained by a method comprising the steps of;
• preparing the granulation solution by mixing one part of the binder with the solvent,
• mixing the active agent risperidone with the rest of the binder and one part of the first diluting agent and sieving them,
• mixing this mixture with the other part of the first diluting agent, the second diluting agent, the binder and the disintegrant,
• granulating the mixture with the granulation solution, drying and sieving,
• adding the lubricant into the mixture and stirring them,
• compressing the final mixture obtained in tablet form and film-coating the tablets with the solution prepared comprising the film coating agent.
The pharmaceutical formulation of the present invention can be used in the treatment of schizophrenia, affective symptoms related to schizophrenia, manic episodes of bipolar disorder and restlessness related to autistic disorder.
EXAMPLE: Formulation and process for preparation of film tablets comprising risperidone
Figure imgf000007_0001
The granulation solution is prepared by mixing one part of the binder with the solvent in obtaining the formulation that shall be used in the present invention. Risperidone, the other part of the binder and one part of the first diluting agent are mixed and sieved. The rest of the first diluting agent, the second diluting agent and powders comprising the disintegrant are stirred in a mixer. The powder mixture obtained is granulated with the granulation solution. The lubricant is added into this mixture and stirred again. The powder mixture obtained is compressed in tablet form and the tablets are coated with the solution comprising the tablet coating agent.

Claims

1. Risperidone formulations formulated in film tablet form, characterized in that said formulations comprise a composition composed of at least two different diluting agents as the diluent and the first diluting agent composing this composition is selected from cellulose based excipients and the second diluting agent is selected from monosaccharides or disaccharides.
2. The pharmaceutical formulation comprising risperidone according to claim 1, characterized in that the ratio of the first diluting agent: the second diluting agent is in the range of 1 : 1 to 1 : 10 by weight.
3. The pharmaceutical formulation comprising risperidone according to claim 2, characterized in that the ratio of the first diluting agen the second diluting agent is in the range of 1 :2 to 1 :8 by weight.
4. The pharmaceutical formulation according to claims 1-3, characterized in that the first diluting agent is selected from a group comprising microcrystalline cellulose, silicated microcrystalline, cellulose acetate, modified cellulose and/or a combination thereof.
5. The pharmaceutical formulation according to claim 4, characterized in that microcrystalline cellulose is preferably used as the first diluting agent.
6. The pharmaceutical formulation comprising risperidone according to claims 1-5, characterized in that the second diluting agent is selected from a group comprising glucose, fructose, galactose, lactose, maltose, sucrose and a combination thereof.
7. The pharmaceutical formulation comprising risperidone according to claim 6, characterized in that lactose is used as the second diluting agent.
8. The pharmaceutical formulation comprising risperidone according to claims 6-7, characterized in that lactose in hydrate form is used as the second diluent.
9. The pharmaceutical formulation comprising risperidone according to claims 6-8, characterized in that lactose monohydrate is used as the second diluent.
10. The pharmaceutical formulation comprising risperidone according to any preceding claims, characterized in that the ratio of microcrystalline cellulose:lactose monohydrate is in the range of 1 : 1 to 1 : 10 by weight.
11. The pharmaceutical formulation according to claim 10, characterized in that the ratio of microcrystalline cellulose: lactose monohydrate is in the range of 1 :2 to 1 :8 by weight.
12. The pharmaceutical formulation comprising risperidone according to any preceding claims, characterized in that the active agent risperidone is used in the range of 0.05- 10% in proportion to total weight of the unit dose amount.
13. The formulation according to claim 12, characterized in that said formulation comprises risperidone in the range of 0.1% to 8% by weight.
14. The formulation according to claims 12-13, characterized in that risperidone is used in the range of 0.5% to 5% by weight in said formulation.
15. The pharmaceutical formulation comprising risperidone according to any preceding claims, characterized in that the active agent risperidone used in the formulation is in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination thereof.
16. The pharmaceutical formulation comprising risperidone according to any preceding claims, characterized in that the diluent composition which is used as the diluent is used in the range of 30% to 99% in proportion to total weight of the unit dose amount.
17. The formulation according to claim 16, characterized in that said formulation comprises diluent in the range of 40 % to 95% by weight.
18. The formulation according to claims 16-17, characterized in that said formulation comprises diluent in the range of 50% to 90% by weight.
19. The pharmaceutical formulation comprising risperidone according to any preceding claims, characterized in that the ratio of risperidone:diluent composition is in the range of 1 :10 to 1 :80 by weight.
20. The formulation according to claim 19, characterized in that said formulation comprises risperidone:diluent composition in the range of 1 : 15 to 1 :70 by weight.
21. The formulation according to claims 19-20, characterized in that said formulation comprises risperidone :diluent composition in the range of 1 :20 to 1:65 by weight.
22. The formulation according to any preceding claims, characterized in that said formulation comprises disintegrant in the range of 1 -50%, binder in the range of 1 - 20%, lubricant in the range of 0.1-5%, the coating agent in the range of 0.5-5% in proportion to total weight of the unit dose amount.
23. The process for preparation of the formulation according to any preceding claims, characterized in that the formulation is obtained by said process comprising the steps of; preparing the granulation solution by mixing one part of the binder with the solvent,
mixing the active agent risperidone with the rest of the binder and one part of the first diluting agent and sieving them,
mixing this mixture with the other part of the first diluting agent, the second diluting agent, the binder and the disintegrant,
granulating the mixture with the granulation solution, then drying and sieving the granules,
adding the lubricant into the mixture and stirring them,
compressing the final mixture obtained in tablet form and film-coating the tablets with the solution comprising the film coating agent.
PCT/TR2012/000231 2011-12-27 2012-12-27 Risperidone formulations Ceased WO2013100876A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR201112995 2011-12-27
TR2011/12995 2011-12-27
TR201203833 2012-04-04
TR2012/03833 2012-04-04

Publications (1)

Publication Number Publication Date
WO2013100876A1 true WO2013100876A1 (en) 2013-07-04

Family

ID=47747754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000231 Ceased WO2013100876A1 (en) 2011-12-27 2012-12-27 Risperidone formulations

Country Status (1)

Country Link
WO (1) WO2013100876A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107028917A (en) * 2017-03-30 2017-08-11 武汉华夏理工学院 Risperidone through gastrointestinal administration is instant and/or fast release solid oral film and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196132A2 (en) 1985-03-27 1986-10-01 Janssen Pharmaceutica N.V. 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives
WO2005123084A1 (en) * 2004-06-15 2005-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating pharmaceutical composition comprising risperidone
EP1985287A2 (en) * 2007-04-25 2008-10-29 Teva Pharmaceutical Industries Ltd. Pharmaceutical Excipient Complex
WO2009043844A2 (en) * 2007-10-01 2009-04-09 Laboratorios Lesvi, S.L. Orodispersible tablets
EP2281557A2 (en) * 2008-04-29 2011-02-09 HanAll Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196132A2 (en) 1985-03-27 1986-10-01 Janssen Pharmaceutica N.V. 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives
WO2005123084A1 (en) * 2004-06-15 2005-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating pharmaceutical composition comprising risperidone
EP1985287A2 (en) * 2007-04-25 2008-10-29 Teva Pharmaceutical Industries Ltd. Pharmaceutical Excipient Complex
WO2009043844A2 (en) * 2007-10-01 2009-04-09 Laboratorios Lesvi, S.L. Orodispersible tablets
EP2281557A2 (en) * 2008-04-29 2011-02-09 HanAll Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107028917A (en) * 2017-03-30 2017-08-11 武汉华夏理工学院 Risperidone through gastrointestinal administration is instant and/or fast release solid oral film and preparation method thereof
CN107028917B (en) * 2017-03-30 2020-07-17 武汉华夏理工学院 Risperidone instant and/or quick-release solid oral film agent for gastrointestinal administration and preparation method thereof

Similar Documents

Publication Publication Date Title
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
KR101977785B1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
JP2013530196A (en) Pharmaceutical composition comprising 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-one lactate monohydrate object
JP5417662B2 (en) Nevirapine sustained release formulation
KR20140092316A (en) Medicinal composition
US20170231969A1 (en) Pharmaceutical Compositions of Edoxaban
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
TWI418370B (en) Dissolution-stable pharmaceutical agent
EP2291079B1 (en) Formulations for cathepsin k inhibitors
ES2377552T3 (en) Easily dissolved and stable compositions of candesartan cilexetil prepared with a wet granulation
WO2016175230A1 (en) Pharmaceutical composition for oral administration
WO2020175897A1 (en) Controlled release formulation containing mirabegron or pharmaceutically acceptable salt thereof
EP2295040A1 (en) Pharmaceutical compositions of pramipexole
CN108174596A (en) Include 8- [(3R) -3- amino -1- piperidyls] -7- (2- butine -1- bases) -3, the pharmaceutical composition of 7- dihydro -3- methyl-1s-[4- methyl -2- quinazolyls) methyl] -1H- purine -2,6- diketone or its pharmaceutically acceptable salt
EP3429562A1 (en) Compositions of deferasirox
EP2644197A1 (en) Novel Pharmaceutical Compositions of Entecavir
WO2011161689A1 (en) Imatinib mesilate pharmaceutical tablet
EP3539536A1 (en) A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
JP2021518422A (en) Pharmaceutical composition containing lenalidomide
JP7355846B2 (en) solid preparation
TW201700094A (en) Method of preparing very slightly soluble drug with solid dosage form
JP5900702B2 (en) Pharmaceutical composition for oral administration
EP3162368A1 (en) Pharmaceutical composition for oral administration
KR20100064015A (en) Controlled-release aceclofenac containing oral drug preparations and it's manufacturing process
WO2020122244A1 (en) Tablet and method for producing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12826584

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12826584

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 12826584

Country of ref document: EP

Kind code of ref document: A1